Document and Entity Information
Document and Entity Information | Jul. 06, 2021 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Description | On July 6, 2021, UNITY Biotechnology, Inc. filed a Current Report on Form 8-K (the “Original Report”) to report that it announced positive data from its Phase 1 safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet or neovascular age-related macular degeneration (AMD) for whom anti-VEGF therapy was no longer considered beneficial. The Original Report included a presentation, filed as Exhibit 99.2, which was incorporated by reference therein. This Form 8-K/A is being filed as an amendment to the Original Report solely to file as Exhibit 99.2 a revised presentation to supersede and replace the original presentation included in the Original Report solely to correct the legend on Slide 18 of the presentation. |
Amendment Flag | true |
Document Period End Date | Jul. 6, 2021 |
Trading Symbol | UBX |
Entity Registrant Name | UNITY BIOTECHNOLOGY, INC. |
Entity Central Index Key | 0001463361 |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity File Number | 001-38470 |
Entity Tax Identification Number | 26-4726035 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 285 East Grand Ave. |
Entity Address, City or Town | South San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94080 |
City Area Code | 650 |
Local Phone Number | 416-1192 |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |